Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements

Andrews, 2015, Hum Exp Toxicol, 34, 1279, 10.1177/0960327115603594

Anselmo, 2019, Nat Rev Drug Discov, 18, 19, 10.1038/nrd.2018.183

Anderson, 2017, Adv Drug Deliv Rev, 112, 101, 10.1016/j.addr.2017.01.003

Chung, 2012, J Drug Target, 20, 481, 10.3109/1061186X.2012.693499

US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed March 16, 2020.

Rule, 2014, Value Health, 17, A537, 10.1016/j.jval.2014.08.1719

Stoner, 2014, Patient, 10.1007/s40271-014-0075-y

Fallowfield, 2015, Breast, 24, 166, 10.1016/j.breast.2015.01.002

Jackisch, 2015, Geburtshilfe Frauenheilkd, 75, 566, 10.1055/s-0035-1546172

Pivot, 2013, Lancet Oncol, 14, 962, 10.1016/S1470-2045(13)70383-8

Turner, 2018, J Pharm Sci, 107, 1247, 10.1016/j.xphs.2018.01.007

Walsh, 2007, Rheumatology (Oxford), 46, 1148, 10.1093/rheumatology/kem074

Hedayati, 2019, PLoS One, 14, e0211783, 10.1371/journal.pone.0211783

Martin, 2013, Transfus Med, 23, 55, 10.1111/j.1365-3148.2012.01201.x

Rule, 2014, J Med Econ, 17, 459, 10.3111/13696998.2014.914033

North, 2015, Clinicoecon Outcomes Res, 7, 423, 10.2147/CEOR.S85599

Papadmitriou, 2015, Facts Views Vis Obgyn, 7, 176

Wu, 2015, Clinicoecon Outcomes Res, 7, 257, 10.2147/CEOR.S83932

Kyriopoulos, 2017, J Cancer Ther, 8, 726, 10.4236/jct.2017.88063

Mateos, 2019, J Clin Oncol, 37, 8005, 10.1200/JCO.2019.37.15_suppl.8005

Chari, 2019, Clin Lymphoma Myeloma Leuk, 19, e16, 10.1016/j.clml.2019.09.023

Usmani, 2019, Blood, 134, 668, 10.1182/blood.2019000667

Jin, 2018, Adv Drug Deliv Rev, 127, 119, 10.1016/j.addr.2018.03.011

Hao Feng, 2020, Colloids Surf B Biointerfaces, 189, 110844, 10.1016/j.colsurfb.2020.110844

Chen, 2020, Sci Adv, 6, eaba7260, 10.1126/sciadv.aba7260

Barolet, 2018, Clin Cosmet Investig Dermatol, 11, 231, 10.2147/CCID.S162724

Pons-Faudoa, 2019, Biomed Microdevices, 21, 47, 10.1007/s10544-019-0389-6

Collins, 2020, J Control Release, 321, 475, 10.1016/j.jconrel.2020.02.036

Amgen. Repatha® (evolocumab). Available from: https://www.repatha.com/how-to-start-repatha-injection/. Accessed October 10, 2019.

Frost, 2007, Expert Opin Drug Deliv, 4, 427, 10.1517/17425247.4.4.427

Mathaes, 2016, J Pharm Sci, 105, 2255, 10.1016/j.xphs.2016.05.029

2015, The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics

Garidel, 2017, Eur J Pharm Biopharm, 119, 353, 10.1016/j.ejpb.2017.06.029

Johnson, 2017, Drug Discov Devel

Wang, 2007, J Pharm Sci, 96, 1, 10.1002/jps.20727

Warne, 2011, Eur J Pharm Biopharm, 78, 208, 10.1016/j.ejpb.2011.03.004

Arecor. Our portfolio; 2020. Available from: http://arecor.com/p^roducts/. Accessed June 11, 2020.

Adocia. BIOCHAPERONE® LISPRO; 2020. Available from: https://www.adocia.com/products/biochaperone-ultra-fast-analog-insulin/. Accessed March 16, 2020.

ExcelseBio. Your medicine, transformed; 2020. http://www.excelsebio.com/partnering. Accessed March 27, 2020.

Xeris Pharmaceuticals. The Xeris solution for conventional formulation limitations. Available from: https://www.xerispharma.com/research-development/technology. Accessed August 31, 2020.

Elektrofi. Redefining the delivery of biologics; 2020. Available from: https://www.elektrofi.com/welcome#technology. Accessed August 31, 2020.

Lindy Biosciences. Microglassification™. Available from: https://www.lindybio.com/technology. Accessed August 31, 2020.

Althea’s new drug formulation technology gains attention from two more top pharmaceutical companies; 2015. Available from: https://ajibio-pharma.com/news-post/altheas-new-drug-formulation-technology-gains-attention-from-two-more-top-pharmaceutical-companies/. Accessed August 31, 2020.

Arecor. What we do. Available from: http://arecor.com/technology/. Accessed August 31, 2020.

Adocia. BioChaperone®. Available from: https://www.adocia.com/technology/biochaperone-technology-2/. Accessed August 31, 2020.

ExcelseBio. EXCELSE™ formulation technology. Available from: http://www.excelsebio.com/technology. Accessed August 31, 2020.

Nemera. Safelia® autoinjector designed to be patients and syringes friendly; 2020. Available from: https://www.nemera.net/wp-content/uploads/2014/06/Nemera_LEAFLET-Safelia_revJune2016.pdf. Accessed August 31, 2020.

Owen Mumford Pharmaceutical Services. Autoject® Visco - a disposable auto-injector developed for high viscosity formulations; 2020. Available from: https://www.ompharmaservices.com/wp-content/uploads/2019/09/Autoject-Visco-Case-Study-Owen-Mumford.pdf. Accessed August 31, 2020.

Owen Mumford Pharmaceutical Services. Autoject® visco; 2020. Available from: https://www.ompharmaservices.com/product-portfolio/autoject-visco/. Accessed August 31, 2020.

Ypsomed. YpsoMate 2.25 – the 2-step large volume autoinjector. Available from: https://yds.ypsomed.com/en/injection-systems/auto-injectors/ypsomate-2-25.html. Accessed August 31, 2020.

SHL Group. Rotaject® technology; 2020. Available from: https://www.shl.group/products-and-services/rotaject-technology-auto-injector/. Accessed August 31, 2020.

Bespak. Vapoursoft® powered auto-injectors; 2020. Available from: https://bespak.com/products/injection-devices/vapoursoft-powered-auto-injectors/. Accessed August 31, 2020.

Collier, 2017, Postgrad Med, 129, 118, 10.1080/00325481.2017.1251291

Amgen launches the ENBREL Mini™ single-dose prefilled cartridge with AutoTouch™ reusable autoinjector that is ergonomically designed for patients; 2017. Available from: https://www.amgen.com/media/news-releases/2017/11/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector-that-is-ergonomically-designed-for-patients/. Accessed August 31, 2020.

Oval Medical Technologies. ArQ®-bios subcutaneous (high viscosities and/or high volumes); 2020. Available from: https://www.ovalmedical.com/portfolio/arq-bios/. Accessed August 31, 2020.

Veilleux, 2018, Drug Deliv Transl Res, 8, 1238, 10.1007/s13346-018-0568-7

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed; 2020. Available from: https://www.ypsomed.com/fr-FR/dernieres-nouvelles-detail/teva-launches-ajovy-for-the-treatment-of-migraine-with-the-ypsomate-autoinjector-from-ypsomed.html. Accessed July 21, 2020.

World Pharmaceutical Frontiers. Latest in injectable technology to enhance biologic development. Available from: http://www.worldpharmaceuticals.net/contractors/world-pharmaceutical-frontiers/latest-in-injectable-technology-to-enhance-biologic-development/. Accessed April 15, 2020.

2017, Challenges in Subcutaneous Product Development of Biologics-Understanding the Impact of Solution Viscosity and Potential Strategies for Enabling SC Delivery of High-Dose And/Or Viscous Biotherapeutics

Yadi, 2020, Drug Dev Deliv

Canè Medical Technology. Infusion pumps. Available from: http://www.infusionpump.it/category/infusion-pumps/. Accessed August 31, 2020.

Sensile Medical. Launched products. Available from: https://www.sensile-medical.com/products.html. Accessed August 31, 2020.

West Pharma. West SmartDose drug delivery platform. Available from: https://www.westpharma.com/products/self-injection-platforms/smartdose. Accessed June 11, 2020.

Alexion. Investor day. Available from: https://ir.alexion.com/static-files/46d4f73c-371a-402d-a271-936d0283b3f6. Accessed October 24, 2019.

Sensile Medical. Innovative micro-infusion pump from gerresheimer subsidiary sensile medical developed and successfully launched for EVER pharma. Available from: https://www.sensile-medical.com/fileadmin/user_upload/News_Events/2019/20190703_Gx_PM_LAUNCH_Mikropumpe_SEN_e.pdf. Accessed March 17, 2020.

BD Completes Clinical Trial for BD Libertas™ wearable injector; 2020. Available from: https://www.bd.com/en-us/company/news-and-media/press-releases/bd-completes-clinical-trial-for-bd-libertas-wearable-injector. Accessed June 11, 2020.

West Pharma. SmartDose® 3.5 injector. Available from: https://www.westpharma.com/products/self-injection-platforms/smartdose/smartdose-3-5. Accessed August 31, 2020.

BD. BD Libertas™ wearable autoinjector. Available from: https://drugdeliverysystems.bd.com/products/self-injection-systems/libertas-wearable-autoinjector. Accessed 31 August 2020.

Bespak. Lapas®: an innovative patch pump device powered by VapourSoft®. Available from: https://bespak.com/services/innovation/patch-pump-lapas/. Accessed August 31, 2020.

Enable Injections. The enable enFuse® on-body platform. Available from: https://enableinjections.com/technology/enfuse-on-body-platform/. Accessed August 31, 2020.

Sonceboz. Sonceboz wearable injectors. Available from: https://www.sonceboz.com/wearable-injectors. Accessed August 31, 2020.

Sorrel Medical. Platform. Available from: https://www.sorrelmedical.com/platform/. Accessed August 31, 2020.

Weibel CDS AG. DrugDeliverySystems. Available from: https://weibelcds.com/products/drug-delivery-systems/. Accessed August 31, 2020.

Ypsomed. YpsoDose – the large volume patch injector. Available from: https://yds.ypsomed.com/en/injection-systems/ypsodose.html. Accessed August 31, 2020.

Atkinson, 1949, Arch Ophthalmol, 42, 628, 10.1001/archopht.1949.00900050638012

Halozyme. Removing traditional limitations on administering therapies: ENHANZE drug delivery technology. Available from: https://www.halozyme.com/enhanze/overview/default.aspx. Accessed October 10, 2019.

Locke, 2019, Drug Deliv, 26, 98, 10.1080/10717544.2018.1551442

Pivot, 2014, Ann Oncol, 25, 1979, 10.1093/annonc/mdu364

Rummel, 2017, Ann Oncol, 28, 836, 10.1093/annonc/mdw685

Ponsford, 2015, Clin Exp Immunol, 182, 302, 10.1111/cei.12694

Morcos, 2013, Int J Clin Pharmacol Ther, 51, 537, 10.5414/CP201847

Morrow, 2011, Diabetes Technol Ther, 13, 1039, 10.1089/dia.2011.0115

Halozyme announces janssen receives FDA approval of DARZALEX FASPRO™ utilizing halozyme’s ENHANZE® technology for the treatment of patients with multiple myeloma; 2020. Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Receives-FDA-Approval-Of-DARZALEX-FASPRO-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-Multiple-Myeloma/default.aspx. Accessed May 14, 2020.

Halozyme announces janssen receives european marketing authorization for subcutaneous DARZALEX® utilizing halozyme’s ENHANZE® technology for the treatment of patients with multiple myeloma; 2020. Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Receives-European-Marketing-Authorization-For-Subcutaneous-DARZALEX-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-Multiple-Myeloma/default.aspx. Accessed May 14, 2020.

Halozyme announces janssen submits new drug application in japan for daratumumab subcutaneous formulation utilizing halozyme’s ENHANZE® technology for patients with multiple myeloma; 2020. Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Submits-New-Drug-Application-In-Japan-For-Daratumumab-Subcutaneous-Formulation-Utilizing-Halozymes-ENHANZE-Technology-For-Patients-With-Multiple-Myeloma/default.aspx. Accessed May 14, 2020.

Halozyme announces roche receives FDA approval for Phesgo™ (fixed-dose combination of Perjeta® and Herceptin® for subcutaneous injection) utilizing halozyme’s ENHANZE® technology for the treatment of patients with HER2-positive breast cancer; 2020. Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Roche-Receives-FDA-Approval-For-Phesgo-Fixed-Dose-Combination-Of-Perjeta-And-Herceptin-For-Subcutaneous-Injection-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-HER2-Positive-Breast-Cancer/default.aspx. Accessed July 21, 2020.

Halozyme. Broad range of partnered and proprietary products; 2020. Available from: https://www.halozyme.com/enhanze/pipeline/default.aspx. Accessed March 17, 2020.

2018, 2014 to 2018: An Update on the State of Wearable Injectors

2019, Evaluating Formulation and Device Factors on Subcutaneous Administration

Jones, 2017, Sci Transl Med, 9, eaaf9166, 10.1126/scitranslmed.aaf9166

Zijlstra, 2018, J Diabetes Sci Technol, 12, 163, 10.1177/1932296817735121

Hamuro, 2017, J Pharm Sci, 106, 2946, 10.1016/j.xphs.2017.05.030

Dias, 2015, AAPS PharmSciTech, 16, 1101, 10.1208/s12249-015-0288-y

Doughty, 2016, J Pharm Sci, 105, 2105, 10.1016/j.xphs.2016.04.009

Berteau, 2015, Med Devices (Auckl), 8, 473, 10.2147/MDER.S91019

Mercadante, 2005, J Pain Symptom Manage, 30, 354, 10.1016/j.jpainsymman.2005.04.004

Schiff, 2017, Rheumatol Ther, 4, 445, 10.1007/s40744-017-0080-4

Baxter, 2017, Vaccine, 35, 4213, 10.1016/j.vaccine.2017.06.029

Sokolowski, 2010, Dent Clin North Am, 54, 731, 10.1016/j.cden.2010.06.012

Gedney, 2007, Clin J Pain, 23, 35, 10.1097/01.ajp.0000210940.04182.a3

Gely, 2018, J Crohns Colitis, 12, S582, 10.1093/ecco-jcc/jjx180.1046

Cohen, 2019, Rheumatol Ther, 6, 245, 10.1007/s40744-019-0152-8

Laursen, 2006, Basic Clin Pharmacol Toxicol, 98, 218, 10.1111/j.1742-7843.2006.pto_271.x

Frenken, 1993, Am J Kidney Dis, 22, 553, 10.1016/s0272-6386(12)80928-0

Yu, 1998, Int J Artif Organs, 21, 341, 10.1177/039139889802100612

Nash, 2016, Rheumatol Ther, 3, 257, 10.1007/s40744-016-0041-3

Martin, 2015, J Adv Pract Oncol, 6, 308, 10.6004/jadpro.2015.6.4.2

Sanchez-Felix, 2020, Adv Drug Deliv Rev, 167, 66, 10.1016/j.addr.2020.05.009